Excellent
Aligned
Patient Risk:
Low
Summary
The provided content mirrors the supplied FARXIGA label excerpts across indications, dosing/administration, contraindications, warnings/precautions, adverse reactions, drug interactions, and specific populations, with no direct conflicts detected.
Category Scores
Accurate Statements
FARXIGA indications include reducing risk of sustained eGFR decline, ESKD, CV death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression; reducing risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure; reducing risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established CV disease or multiple CV risk factors; and as adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
Section 1 (INDICATIONS AND USAGE) in provided label excerpt
Limitations of use: not recommended for glycemic control in type 1 diabetes mellitus; not recommended to improve glycemic control in type 2 diabetes mellitus with eGFR <45 mL/min/1.73 m2 (likely ineffective); not recommended for treatment of CKD in polycystic kidney disease or patients requiring or with recent history of immunosuppressive therapy for kidney disease (not expected to be effective).
Section 1 (Limitations of Use) in provided label excerpt
Before initiation assess renal function and assess volume status; correct volume depletion prior to initiation.
Section 2.1 Testing Prior to Initiation of FARXIGA in provided label excerpt
For glycemic control in adults and pediatric patients aged 10+ years with type 2 diabetes mellitus: start 5 mg orally once daily; increase to 10 mg once daily for additional glycemic control.
Section 2.2 in provided label excerpt
For glycemic control in renal impairment: if eGFR ≥45 mL/min/1.73 m2 dosage same as normal renal function; if eGFR <45 mL/min/1.73 m2 not recommended (likely ineffective).
Section 2.2 in provided label excerpt
For other indications in adults: recommended dosage is 10 mg orally once daily for chronic kidney disease at risk of progression, heart failure, and to reduce risk of hospitalization for heart failure in type 2 diabetes with established CV disease or multiple CV risk factors.
Section 2.3 in provided label excerpt
For adults with renal impairment receiving FARXIGA for indications other than glycemic control: eGFR ≥25 mL/min/1.73 m2 same as normal renal function; initiation not recommended if eGFR <25; if eGFR falls below 25 while receiving treatment, patients may continue 10 mg once daily.
Section 2.3 in provided label excerpt
For temporary interruption for surgery: withhold FARXIGA for at least 3 days prior to surgery/procedures associated with prolonged fasting; resume when clinically stable and oral intake resumed.
Section 2.4 in provided label excerpt
Missed dose: take as soon as possible; do not double up the next dose.
Section 2.5 in provided label excerpt
Contraindication: history of serious hypersensitivity reaction to dapagliflozin or excipients; serious hypersensitivity reactions including anaphylaxis and angioedema have been reported.
Section 4 (CONTRAINDICATIONS) in provided label excerpt
Warnings/precautions include: increased risk of diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis; withhold in temporary clinical situations that could predispose patients to ketoacidosis; resume when clinically stable and oral intake resumed. Volume depletion/intravascular volume depletion with possible symptomatic hypotension/creatinine changes and post-marketing reports of acute kidney injury. Increased risk of genitourinary infections including serious infections; if suspected, discontinue and promptly institute appropriate intervention. Hypoglycemia risk increased when combined with insulin or insulin secretagogues; lower doses may be required.
Sections 5.1–5.4 in provided label excerpt
Adverse reactions listed include diabetic ketoacidosis in patients with type 1 diabetes mellitus and other ketoacidosis; volume depletion; genitourinary infections; and hypoglycemia with concomitant use with insulin and insulin secretagogues.
Section 6 (ADVERSE REACTIONS) and 6.1 in provided label excerpt
Drug interactions: insulin/insulin secretagogues may increase hypoglycemia risk; lithium may have decreased serum lithium concentrations requiring more frequent monitoring; monitoring glycemic control with urine glucose tests is not recommended; 1,5-anhydroglucitol (1,5-AG) assay is unreliable and not recommended.
Section 7 (DRUG INTERACTIONS) Table 4 in provided label excerpt
Pregnancy: not recommended during second and third trimesters of pregnancy. Lactation: use is not recommended while breastfeeding. Pediatric: safety/effectiveness established for adjunct to diet/exercise to improve glycemic control in type 2 diabetes in patients aged 10+; safety/effectiveness not established for reducing risk of sustained eGFR decline, CV death, or hospitalization for heart failure in pediatric patients.
Sections 8.1, 8.2, and 8.4 in provided label excerpt
Geriatric: no dosage change recommended based on age; in patients ≥65 a higher proportion experienced adverse reactions of hypotension.
Section 8.5 in provided label excerpt
Renal impairment: patients with diabetes and renal impairment may be more likely to experience hypotension and at higher risk of acute kidney injury secondary to volume depletion; use for glycemic control in patients without established CV disease or CV risk factors is not recommended when eGFR <45 mL/min/1.73 m2.
Section 8.6 in provided label excerpt
Unsupported Statements
Contradictions
Important Omissions
Boxed warning content (if any) was not provided in the supplied excerpt set, so boxed-warning alignment could not be assessed.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No unsupported or contradictory prescribing claims were identified relative to the provided FARXIGA label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Aligned
Primary Issue
Suggested Improvement